This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
January 16, 2013 /PRNewswire/ --
Breakthrough technology generates superior human single domain antibody VHfragments in a transgenic mouse
Crescendo Biologics Limited (Crescendo) today announces the Crescendo Mouse, a breakthrough in antibody fragment technology which allows the efficient generation of high-quality fully human single domain antibody V
H fragments from a transgenic mouse.
H fragments are next-generation antibody-based therapeutic proteins that have exciting applications beyond the scope of full length antibodies. They are the smallest antibody fragments that retain the ability to bind antigens specifically and with high affinity and, when generated in the Crescendo Mouse, human V
H have superior biophysical properties that make them highly attractive drug products. V
H fragments can be formulated for topical delivery, are highly amenable to modular engineering of bispecific and multivalent products, have superior tissue penetration characteristics, and are simple to manufacture in microbial systems.
Mike Romanos, CEO of Crescendo, said, "The majority of recent approvals for monoclonal antibody therapeutics have been fully human and derived from transgenic mice. Transgenic mice are highly valued for their ability to generate fully human antibodies that develop
in vivo, through the natural process of B cell maturation, and require little or no further manipulation to create highly potent therapeutics. The Crescendo Mouse combines all the benefits of transgenic mouse technology with the excellent drug qualities of single domain V
H fragments. We believe this will enable rapid generation of superior therapeutic products, and fully realise the potential of human V
H fragments in the development of our pipeline and that of future partners."
Key to generation of V
H fragments in the mouse is Crescendo's proprietary triple knock out (TKO) background, which is completely devoid of all endogenous immunoglobulin chains, and therefore enables
in vivo maturation of human V
H single domains uncontaminated by association with any light chains. B cell development within the Crescendo Mouse is driven from a construct introduced into the TKO background that combines human V- D- and J- genes, together with murine constant and regulatory regions, to generate heavy chain only antibodies. The power of the mouse immune system is consequently fully harnessed to drive B cell development and maturation, leading to a diverse repertoire of fully-human V
H domains with superior stability and solubility.
The Crescendo Mouse responds robustly to immunisation with target proteins and
in vivo B cell maturation yields diverse human V
H domains, from all V
H families, which have also undergone somatic hypermutation. Because the antibody response following immunisation is entirely encompassed within the V
H domain, Crescendo has been able to develop a fully integrated discovery process utilising
in vitro display to comprehensively mine and rapidly identify V
H drug candidates directly from immunised mice. Purified V
H fragments have been shown to bind immunogen with high affinity, exhibit very high thermostability and have excellent expression levels. These data indicate that B cell maturation in the Crescendo Mouse is driving selection and optimisation of matured human V
Hdomains, with all of the properties that make them highly potent, drug quality antibody-based therapeutics.
Crescendo has commenced discovery for its own pipeline of therapeutic products, and is in discussion with pharmaceutical companies interested in accessing the Crescendo Mouse.